The World Health Organization (WHO) has produced a draft Question and Answer (Q&A) document that gives additional clarification to its 2009 guidelines for evaluating similar biotherapeutic products, particularly with respect to evaluating biosimilars of monoclonal antibodies.
The World Health Organization (WHO) has produced a draft Question and Answer (Q&A) document that gives additional clarification to its 2009 guidelines for evaluating similar biotherapeutic products, particularly with respect to evaluating biosimilars of monoclonal antibodies.
The contents of the draft document, which the WHO emphasizes must be read in the context of the guidelines, were selected on the basis of the questions most frequently asked by regulators during implementation workshops for the WHO guideline document, which seeks to provide globally acceptable principles for the licensing of follow-on biologics (except for vaccines and plasma-derived products, for which the organization provides separate recommendations and guidance). The WHO says that the guidelines can be adopted in whole or in part by any national regulatory authority worldwide.
The Q&A follows 6 broad categories: the concept for licensing similar biotherapeutic products, reference biotherapeutic products, quality, nonclinical evaluation, clinical evaluation, and pharmacovigilance. Topics addressed in the Q&A range from basic definitions of terms such as “similar biotherapeutic product” and “reference biotherapeutic product” to more technical issues, such as how many batches of a product should be tested in comparability studies, how comprehensive an evaluation of glycan structure should be, and how updates to safety information for a reference product should be handled for approved biosimilars, among others.
The WHO invites stakeholders to submit written comments on the draft to the Department of Essential Medicines and Health Products by September 20, 2018. After the organization’s Expert Committee on Biological Standardization has had the opportunity to review the comments and discuss any alterations to the document, the outcome of its deliberations will be published in the WHO Technical Report Series.
Additional initiatives of the WHO on promoting biosimilars include its pilot program to prequalify biosimilars for oncology indications. In May 2017, the organization announced that it would launch the pilot, which intended to expand access to some of the most expensive biologics in low- and middle-income countries.
Under the program, if the WHO finds that a biosimilar is comparable to its reference in terms of quality, safety, and efficacy, WHO will list the product, making it eligible for procurement by United Nations agencies. It will also allow some middle- and low-income countries that rely on WHO prequalification to make the listed biosimilar available to patients.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.